WuXi Biologics signed letter of intent for longterm vaccine manufacturing contract

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

04:54 EDT 22 May 2019 | Pharmaceutical Business Review

WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology (stock code 603718.SH). The business model of WuXi Vaccines is

The post WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract appeared first on Pharmaceutical Business review.

More From BioPortfolio on "WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract"